Yahoo
NYSE - Delayed Quote USD

Globus Medical, Inc. (GMED)

81.26 +0.36 (+0.44%)
At close: October 28 at 4:00:02 PM EDT
82.20 +0.94 (+1.16%)
Pre-Market: 7:10:12 AM EDT
Trade GMED on Coinbase
Chart Range Bar
Loading chart for GMED
  • Previous Close 80.90
  • Open 80.47
  • Bid --
  • Ask 83.00 x 10000
  • Day's Range 80.23 - 81.73
  • 52 Week Range 59.51 - 101.40
  • Volume 772,383
  • Avg. Volume 1,404,696
  • Market Cap (intraday) 10.91B
  • Beta (5Y Monthly) 0.96
  • PE Ratio (TTM) 20.84
  • EPS (TTM) 3.90
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 100.92
  • Zacks Rating Bullish

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

www.globusmedical.com

6,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GMED
6.93%
S&P 500 (^GSPC)
13.13%

1-Year Return

GMED
29.50%
S&P 500 (^GSPC)
12.38%

3-Year Return

GMED
77.97%
S&P 500 (^GSPC)
88.08%

5-Year Return

GMED
5.72%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 789.61M
Earnings 151.57M
Profit Margin 19.20%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
800M
16.0%
17.0%
18.0%
19.0%

Analyst Insights

View More

Analyst Price Targets

84.00
100.92 Average
81.26 Current
125.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/1/2026
Analyst RBC Capital
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 115 -> 85

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.02%

  • Return on Assets (ttm)

    8.74%

  • Return on Equity (ttm)

    11.81%

  • Revenue (ttm)

    3.14B

  • Net Income Avi to Common (ttm)

    535.43M

  • Diluted EPS (ttm)

    3.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    595.14M

  • Total Debt/Equity (mrq)

    2.35%

  • Levered Free Cash Flow (ttm)

    554.19M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: